In contrast to the other T cell-based therapies discussed in this review, TILs are a polyclonal population of CD4+ and CD8+ T cells that are selected on the basis of their presence in the tumor microenvironment rather than their ability to recognize a specific target antigen [5,8,10]. Here, CD8A is linked to neoplasm.